Alberto Briganti

New Capabilities

Presented the PROTEUS substudy at ESMO Congress 2026

Apalutamide taken for six months before and after prostate cancer surgery cut the risk of recurrence or death by 62% compared with surgery alone in a 408-patient substudy of the PROTEUS trial. Johnson & Johnson reported the results on Oct. 24, 2026; they were presented at the ESMO Congress in Madrid and accepted for publication by European Urology.

Updated Oct 26